Consult with our medical team to determine if this treatment is appropriate for your health status and goals.
FDA Provided Clarity on GHK-Cu On May 14, 2026, the FDA restored non-injectable GHK-Cu to Category 1 of the 503A bulk drug substances list, confirming that the earlier withdrawal applied only to injectable routes of administration
Second, many patients using GHK-Cu are also using it alongside GLP-1s, peptide combinations, or NAD protocols
We expect the proposed strategy for constructing BsNb will provide a robust and general platform useful for immunotherapy of other cancers
Results: Endotoxins Products passing endotoxin testing included Ocean Pharmaceutical and Hospira vial #2
Things like the weather, what you eat, and other health issues matter too